Affinia Therapeutics Inc. Watch

from S-1 18 pages 1. Position. Your Employment Will Be Effective as of December 6th, 2021 (The “Start Date”). Your Initial Title Will Be Chief Financial Officer, and You Will Initially Report to the Company’s Chief Executive Officer (“CEO”). This Is a Full-Time Position Pursuant to Which You Will Devote Substantially All of Your Business Time, Attention and Energies to the Tasks and Duties of Your Position as Assigned by the Company. at All Times You Will Be Expected to Abide by All Policies and Procedures of the Company as in Effect From Time to Time. While You Are Employed by the Company, You Will Not Engage in Any Other Employment, Consulting or Other Business Activity That Would Create a Conflict of Interest With the Company. by Signing This Offer Letter, You Confirm to the Company That, as of Your Start Date, You Have No Contractual Commitments or Other Legal Obligations That Would Prohibit You From Performing Your Duties for the Company. 2. Cash Compensation

from S-1 18 pages 2. Cash Compensation

from S-1 15 pages Employment Agreement

from S-1 83 pages Tdtx, Inc. 2019 Equity Incentive Plan Adopted by the Board of Directors: November 25, 2019 Approved by the Stockholders: November 25, 2019 Termination Date: November 24, 2029

from S-1 24 pages Manufacturing Services Agreement

from S-1 28 pages Sponsored Research Collaboration Agreement by and Between the Institute of Molecular and Clinical Ophthalmology Basel and Affinia Therapeutics Inc

from S-1 6 pages Option Agreement

from S-1 11 pages Collaboration-Agreement

from S-1 70 pages Strategic Collaboration and License Agreement Between Vertex Pharmaceuticals Incorporated and Affinia Therapeutics Inc. Strategic Collaboration and License Agreement

from S-1 54 pages Exclusive License Agreement Between Lonza Houston, Inc. and Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute, Inc. and Tdtx, Inc. September 9, 2019

from DRS/A 24 pages Manufacturing Services Agreement

from DRS/A 28 pages Sponsored Research Collaboration Agreement by and Between the Institute of Molecular and Clinical Ophthalmology Basel and Affinia Therapeutics Inc

from DRS/A 6 pages Option Agreement

from DRS/A 11 pages Collaboration-Agreement

from DRS/A 70 pages Strategic Collaboration and License Agreement Between Vertex Pharmaceuticals Incorporated and Affinia Therapeutics Inc. Strategic Collaboration and License Agreement

from DRS/A 54 pages Exclusive License Agreement Between Lonza Houston, Inc. and Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute, Inc. and Tdtx, Inc. September 9, 2019

from DRS 83 pages Tdtx, Inc. 2019 Equity Incentive Plan Adopted by the Board of Directors: November 25, 2019 Approved by the Stockholders: November 25, 2019 Termination Date: November 24, 2029